 | • レポートコード：QFJ1-3957 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、がんモノクローナル抗体提携条件＆契約の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（資産購入、共同研究開発、合弁事業、ライセンス供与、その他）、用途別市場規模（製薬産業、バイオテクノロジー、医療、教育＆研究所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・がんモノクローナル抗体提携条件＆契約の市場動向 ・企業の競争状況、市場シェア ・がんモノクローナル抗体提携条件＆契約の種類別市場規模と予測2016-2027（資産購入、共同研究開発、合弁事業、ライセンス供与、その他） ・がんモノクローナル抗体提携条件＆契約の用途別市場規模と予測2016-2027（製薬産業、バイオテクノロジー、医療、教育＆研究所、その他） ・がんモノクローナル抗体提携条件＆契約の北米市場規模2016-2027（アメリカ、カナダ） ・がんモノクローナル抗体提携条件＆契約の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・がんモノクローナル抗体提携条件＆契約のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・がんモノクローナル抗体提携条件＆契約の中南米市場規模2016-2027（メキシコ、ブラジル） ・がんモノクローナル抗体提携条件＆契約の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（3SBio、4D Pharma、Abbvie、Abzena、Adaptive Biotechnologies、Aeglea BioTherapeutics、Agenus Bio、Ascension、Ascentage Pharma、Aslan Pharma、Telix Pharmaceuticals、Basilea Pharmaceutica、Bavarian Nordic、Baxalta、Bayer、Cantargia、Apollomics、Chiome Bioscience、Clovis Oncology） ・結論 |
Monoclonal antibodies are single cell clones of antibodies, a biochemical tool that allows scientists to create antibodies that combine the specificity of specific substances. There are many reasons for the medical community to support the use of monoclonal antibodies in cancer treatment. There are a few clinical trials.
Market Analysis and Insights: Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market
The global Cancer Monoclonal Antibody Partnering Terms and Agreements market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Monoclonal Antibody Partnering Terms and Agreements market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Monoclonal Antibody Partnering Terms and Agreements market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Monoclonal Antibody Partnering Terms and Agreements market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Monoclonal Antibody Partnering Terms and Agreements market.
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Scope and Market Size
Cancer Monoclonal Antibody Partnering Terms and Agreements market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cancer Monoclonal Antibody Partnering Terms and Agreements market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Asset Purchase
Collaborative R&D
Joint Venture
Licensing
Other
Segment by Application
Pharmaceutical Industry
Biotechnology
Medical Care
Education and Research
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
3SBio
4D Pharma
Abbvie
Abzena
Adaptive Biotechnologies
Aeglea BioTherapeutics
Agenus Bio
Ascension
Ascentage Pharma
Aslan Pharma
Telix Pharmaceuticals
Basilea Pharmaceutica
Bavarian Nordic
Baxalta
Bayer
Cantargia
Apollomics
Chiome Bioscience
Clovis Oncology
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Asset Purchase
1.2.3 Collaborative R&D
1.2.4 Joint Venture
1.2.5 Licensing
1.2.6 Other
1.3 Market by Application
1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Medical Care
1.3.5 Education and Research
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2016-2027)
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Regions
2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Share by Regions (2016-2021)
2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Regions (2022-2027)
2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Dynamic
2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends
2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue
3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2016-2021)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2016-2021)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2020
3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2016-2021)
4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2022-2027)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application
5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2016-2021)
5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2016-2027)
6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
6.2.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021)
6.2.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027)
6.2.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2027)
6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
6.3.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021)
6.3.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027)
6.3.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2027)
6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
6.4.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021)
6.4.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2016-2027)
7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
7.2.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021)
7.2.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027)
7.2.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2027)
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
7.3.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021)
7.3.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027)
7.3.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2027)
7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
7.4.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021)
7.4.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2016-2027)
8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
8.2.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2027)
8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
8.3.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2027)
8.4 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region
8.4.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2016-2027)
9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
9.2.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021)
9.2.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027)
9.2.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2027)
9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
9.3.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021)
9.3.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027)
9.3.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2027)
9.4 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
9.4.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021)
9.4.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2016-2027)
10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
10.2.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2027)
10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
10.3.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2027)
10.4 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
10.4.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 3SBio
11.1.1 3SBio Company Details
11.1.2 3SBio Business Overview
11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.1.5 3SBio Recent Development
11.2 4D Pharma
11.2.1 4D Pharma Company Details
11.2.2 4D Pharma Business Overview
11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.2.5 4D Pharma Recent Development
11.3 Abbvie
11.3.1 Abbvie Company Details
11.3.2 Abbvie Business Overview
11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.3.5 Abbvie Recent Development
11.4 Abzena
11.4.1 Abzena Company Details
11.4.2 Abzena Business Overview
11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.4.5 Abzena Recent Development
11.5 Adaptive Biotechnologies
11.5.1 Adaptive Biotechnologies Company Details
11.5.2 Adaptive Biotechnologies Business Overview
11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.5.5 Adaptive Biotechnologies Recent Development
11.6 Aeglea BioTherapeutics
11.6.1 Aeglea BioTherapeutics Company Details
11.6.2 Aeglea BioTherapeutics Business Overview
11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.6.5 Aeglea BioTherapeutics Recent Development
11.7 Agenus Bio
11.7.1 Agenus Bio Company Details
11.7.2 Agenus Bio Business Overview
11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.7.5 Agenus Bio Recent Development
11.8 Ascension
11.8.1 Ascension Company Details
11.8.2 Ascension Business Overview
11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.8.5 Ascension Recent Development
11.9 Ascentage Pharma
11.9.1 Ascentage Pharma Company Details
11.9.2 Ascentage Pharma Business Overview
11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.9.5 Ascentage Pharma Recent Development
11.10 Aslan Pharma
11.10.1 Aslan Pharma Company Details
11.10.2 Aslan Pharma Business Overview
11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.10.5 Aslan Pharma Recent Development
11.11 Telix Pharmaceuticals
11.11.1 Telix Pharmaceuticals Company Details
11.11.2 Telix Pharmaceuticals Business Overview
11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.11.5 Telix Pharmaceuticals Recent Development
11.12 Basilea Pharmaceutica
11.12.1 Basilea Pharmaceutica Company Details
11.12.2 Basilea Pharmaceutica Business Overview
11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.12.5 Basilea Pharmaceutica Recent Development
11.13 Bavarian Nordic
11.13.1 Bavarian Nordic Company Details
11.13.2 Bavarian Nordic Business Overview
11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.13.5 Bavarian Nordic Recent Development
11.14 Baxalta
11.14.1 Baxalta Company Details
11.14.2 Baxalta Business Overview
11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.14.5 Baxalta Recent Development
11.15 Bayer
11.15.1 Bayer Company Details
11.15.2 Bayer Business Overview
11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.15.5 Bayer Recent Development
11.16 Cantargia
11.16.1 Cantargia Company Details
11.16.2 Cantargia Business Overview
11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.16.5 Cantargia Recent Development
11.17 Apollomics
11.17.1 Apollomics Company Details
11.17.2 Apollomics Business Overview
11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.17.5 Apollomics Recent Development
11.18 Chiome Bioscience
11.18.1 Chiome Bioscience Company Details
11.18.2 Chiome Bioscience Business Overview
11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
11.18.5 Chiome Bioscience Recent Development
11.18 Clovis Oncology
.1 Clovis Oncology Company Details
.2 Clovis Oncology Business Overview
.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
.5 Clovis Oncology Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Asset Purchase
Table 3. Key Players of Collaborative R&D
Table 4. Key Players of Joint Venture
Table 5. Key Players of Licensing
Table 6. Key Players of Other
Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2016-2021)
Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2022-2027)
Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends
Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players (2016-2021)
Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2020)
Table 20. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
Table 24. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2016-2021)
Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2016-2021)
Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2022-2027) & (US$ Million)
Table 64. 3SBio Company Details
Table 65. 3SBio Business Overview
Table 66. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 67. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 68. 3SBio Recent Development
Table 69. 4D Pharma Company Details
Table 70. 4D Pharma Business Overview
Table 71. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 72. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 73. 4D Pharma Recent Development
Table 74. Abbvie Company Details
Table 75. Abbvie Business Overview
Table 76. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 77. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 78. Abbvie Recent Development
Table 79. Abzena Company Details
Table 80. Abzena Business Overview
Table 81. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 82. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 83. Abzena Recent Development
Table 84. Adaptive Biotechnologies Company Details
Table 85. Adaptive Biotechnologies Business Overview
Table 86. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 87. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 88. Adaptive Biotechnologies Recent Development
Table 89. Aeglea BioTherapeutics Company Details
Table 90. Aeglea BioTherapeutics Business Overview
Table 91. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 92. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 93. Aeglea BioTherapeutics Recent Development
Table 94. Agenus Bio Company Details
Table 95. Agenus Bio Business Overview
Table 96. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 97. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 98. Agenus Bio Recent Development
Table 99. Ascension Company Details
Table 100. Ascension Business Overview
Table 101. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 102. Ascension Recent Development
Table 103. Ascentage Pharma Company Details
Table 104. Ascentage Pharma Business Overview
Table 105. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 106. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 107. Ascentage Pharma Recent Development
Table 108. Aslan Pharma Company Details
Table 109. Aslan Pharma Business Overview
Table 110. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 111. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 112. Aslan Pharma Recent Development
Table 113. Telix Pharmaceuticals Company Details
Table 114. Telix Pharmaceuticals Business Overview
Table 115. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 116. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 117. Telix Pharmaceuticals Recent Development
Table 118. Basilea Pharmaceutica Company Details
Table 119. Basilea Pharmaceutica Business Overview
Table 120. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 121. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 122. Basilea Pharmaceutica Recent Development
Table 123. Bavarian Nordic Company Details
Table 124. Bavarian Nordic Business Overview
Table 125. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 126. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 127. Bavarian Nordic Recent Development
Table 128. Baxalta Company Details
Table 129. Baxalta Business Overview
Table 130. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 131. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 132. Baxalta Recent Development
Table 133. Bayer Company Details
Table 134. Bayer Business Overview
Table 135. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 136. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 137. Bayer Recent Development
Table 138. Cantargia Company Details
Table 139. Cantargia Business Overview
Table 140. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 141. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 142. Cantargia Recent Development
Table 143. Apollomics Company Details
Table 144. Apollomics Business Overview
Table 145. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 146. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 147. Apollomics Recent Development
Table 148. Chiome Bioscience Company Details
Table 149. Chiome Bioscience Business Overview
Table 150. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 151. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 152. Chiome Bioscience Recent Development
Table 153. Clovis Oncology Company Details
Table 154. Clovis Oncology Business Overview
Table 155. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 156. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021) & (US$ Million)
Table 157. Clovis Oncology Recent Development
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2020 VS 2027
Figure 2. Asset Purchase Features
Figure 3. Collaborative R&D Features
Figure 4. Joint Venture Features
Figure 5. Licensing Features
Figure 6. Other Features
Figure 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2020 VS 2027
Figure 8. Pharmaceutical Industry Case Studies
Figure 9. Biotechnology Case Studies
Figure 10. Medical Care Case Studies
Figure 11. Education and Research Case Studies
Figure 12. Other Case Studies
Figure 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
Figure 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions: 2020 VS 2027
Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Regions (2022-2027)
Figure 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2020
Figure 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2020
Figure 21. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2016-2021)
Figure 22. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2022-2027)
Figure 23. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2016-2027)
Figure 25. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2016-2027)
Figure 26. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2016-2027)
Figure 27. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2016-2027)
Figure 31. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2016-2027)
Figure 32. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2016-2027)
Figure 33. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2016-2027)
Figure 43. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2016-2027)
Figure 51. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2016-2027)
Figure 52. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2016-2027)
Figure 53. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2016-2027)
Figure 59. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 63. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 64. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 65. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 66. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 67. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 68. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 69. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 70. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 71. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 72. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 73. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 74. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 75. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 76. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 77. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 78. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 79. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 80. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2016-2021)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed
世界のドラッグデリバリー提携条件＆契約書市場規模・現状・予測（2021年-2027年） Drug delivery refers to approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body for therapeutic effect. Market Analysis and Insights: Global Drug Delivery Partnering Terms and Agreements Market The global Drug Delivery Partnering Terms and Agreement…- 世界の狂犬病モノクローナル抗体市場規模・現状・予測（2021年-2027年） Anti-rabies virus monoclonal antibody is a passive immune preparation, which has the same or better neutralizing effect as rabies immunoglobulin. The development of anti-rabies virus monoclonal antibodies to replace traditional human immunoglobulin and immune antiserum products is an important direc…
- モノクローナル抗体診断試薬のグローバル市場2021 Monoclonal Antibody Diagnostic Reagents are reagents whose active ingredients are monoclonal antibodies to identify infectious agents, abnormal cells or elements of the body's response to disease. At present, in the foreign industrial developed countries the Monoclonal Antibody Diagnostic Reagents i…
- 世界の二重特異性モノクローナル抗体市場規模・現状・予測（2021年-2027年） A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antig…
- 世界のウサギ抽出抗DPH5抗体市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Anti-DPH5 Antibody Produced In Rabbit Market The global Anti-DPH5 Antibody Produced In Rabbit market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and…